It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the treatment of. Theratechnologies develops and commercializes innovative therapies. Theratechnologies Inc. Vancouver, Canada –– TheNewswire - April 7, 2022 - Teuton Resources Corp. communications@theratech. 2015 Peel Street, 11th Floor Montréal, Québec Canada H3A 1T8 Phone: 514 336-7800 Fax: 514 331-9691 Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management. By continuing to use our service, you agree to our use of cookies. ) Clinical-stage pharmaceutical company Theralase Technologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced today that it will report financial results for its second quarter of fiscal 2022 ended May 31 on Thursday, July 14, 2022. Further. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it will report financial results for its third quarter of fiscal 2022 ended August 31, on Thursday, October 13. Philippe Dubuc Senior Vice President and Chief Financial Officer Phone: +1-438-315-6608 ir@theratech. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the. 1 Wall Street analysts have set twelve-month price targets for Theratechnologies in the last year. 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theratechnologies Inc. . NCU. It also helps investors analyze the systematic and unsystematic risks associated with investing in Theratechnologies over a specified time horizon. 7 ( 1D) About THTX In 2022, THTX's revenue was 80. 8 and 1. This peptide-drug conjugate (PDC) is the lead candidate stemming from Theratechnologies’ SORT1+ Technology™ in oncology. During the last trading day the stock fluctuated 12. Cookies are used to offer you a better browsing experience and to analyze our traffic. TH | May 19, 2023. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a commercial-stage biopharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical. com. 19, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Announces Operational Update - read this article along with other careers information, tips and advice on BioSpace Theratechnologies Inc. (THTX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Stockhouse. By continuing to use our service, you agree to our use of cookies. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. By continuing to use our service, you agree to our use of cookies. Theratechnologies. com uses cookies on this site. Cookies are used to offer you a better browsing experience and to analyze our traffic. has received a $100 million binding commitment with respect to a non-dilutive term loan with an affiliate of Marathon Asset Management. MONTREAL, Aug. Cookies are used to offer you a better browsing experience and to. . MONTREAL, Nov. Theratechnologies's earnings have been declining at an average annual rate of -35. Theratechnologies is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies. 40%. : 001-35203 Mr. 72%. The abstracts are now available at aacr. Second quarter 2022 earnings: Revenues miss analyst expectations Jul 15. 69, 1. We also use them to. Theratechnologies Inc. By continuing to use our service, you agree to our use of cookies. Canada’s largest financial portal for Canadian small-cap investors is right here at Stockhouse where our Bullboards are a leading forum. The SORT1 receptor plays a significant role in protein internalization, sorting and trafficking. Stockhouse. (TH. : Nasdaq Theratechnologies Inc. 3089 Background: SORT1 is expressed in a variety of tumors when compared to most healthy tissue. Stockhouse. com uses cookies on this site. - On track to meet FY2022. July 24 - Heron Therapeutics: Heron is turning to layoffs for the second time in 13 months to cut. (TH. com uses cookies on this site. Stockhouse. (2013-04-03 | TSX:TH) Theratechnologies Inc. Story. 04) earnings per share (EPS) for the quarter. (TSE:TH) posted its quarterly earnings data on Tuesday, September, 26th. By exploiting the SORT1 function in ligand internalization, a new anticancer treatment strategy was designed to target SORT1‐positive TNBC‐derived cells both in vitro and in two in vivo tumor xenografts. com. Theratechnologies (TSX:TH) has announced a loan of up to US$100M from Marathon Asset Management. (882) posted 3 minutes ago. Data Link's cloud-based technology platform allows you to search, discover and access data and analytics for seamless integration via cloud APIs. Theratechnologies affirms fiscal 2022 revenue to be in the range of $79 million and $84 million for full fiscal 2022, or growth of the commercial portfolio to be in the range of 13% and 20% as compared to the 2021 fiscal year. Stockhouse. Theratechnologies Inc. Saint-Laurent, Canada. The company reported ($0. Betteryear2. com. (TH) has had its first patient receive a dose of TH1902, for the treatment of sortilin positive (SORT1+) solid tumours. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Statut du système de négociation. Volatility Over Time: TH's weekly volatility has increased from 16% to 25% over the past year. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. Get the latest Sernova Corp (SVA) real. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Browse posts by Sector and Subsector. Stockhouse. [email protected] Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update T. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. TH | September 5, 2023. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. [email protected] Inc: Overview. B2Gold Declares Fourth Quarter 2023 Dividend. m. 9 million as at August 31, 2023. (THTX) NasdaqCM - NasdaqCM Real Time Price. Share your ideas and get valuable insights from the community of like minded traders and investors Headquarters. Stockhouse. (2022-07-27 | TSX:TH) Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement. (2022-10-03 | TSX:TH) Theratechnologies' Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population. Pour les émetteurs. org. 4% annually. Theratechnologies (TH) and partners contributed $2 million for a research project for a new treatment for metastatic cancer. 1300 (+9. We also use them to share usage information with our partners. TORONTO, May 19, 2023 /CNW/ - This press release is being disseminated as required by. Proceeds to Be Used to Redeem All of the Outstanding 5. The company had revenue of $20. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies Reports Financial Results for the Third Quarter and Nine Months of Fiscal 2023 and Provides Business Updates. 22, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies inc. Theratechnologies' CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City. This news release constitutes a “designated news release” for the purposes of the Company’s. - Q3 2022 North American Revenue Growth of 19%. - Issued and outstanding common shares to be consolidated on the basis of 1 post. com uses cookies on this site. Amendment Withdraws the Condition to File HFS Report to the FDA to Access the US$20 Million Second Tranche. Further. Stable Share Price: TH is more volatile than 90% of Canadian stocks over the past 3 months, typically moving +/- 25% a week. T. Free cash flow. MONTREAL, May 25, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Theratechnologies reduces R&D head count to compensate for sales setback. T. According to 3 analysts, the average rating for THTX stock is "Buy. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. (TSX: TH, Forum) noted that its Q1 2022 consolidated sales grew 20%, supported by 35% growth in sales of EGRIFTA SV formulation. GlobeNewswire. Early Warning Report Issued Pursuant to National Instrument 62-103 - Acquisition of Securities of Theratechnologies Inc. Conjugating the short peptide with various anti-cancer agents allows for. Theratechnologies layoffs. US Headquarters. US Headquarters. 08). Paul Levesque - President. Stockhouse. 81 million for the quarter. Cookies are used to. Vice President, Communications and Corporate Affairs. MONTREAL, Aug. , a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. T. , alpha and beta) for all equities such as Theratechnologies. (“Teuton” or “the Company”) (TSXV:TUO) (Frankfurt:TFE) has received news from its joint venture partner, Tudor Gold Corp. MONTREAL, Oct. stock news by MarketWatch. About Theratechnologies. By continuing to use our service, you agree to our use of cookies. It’s lead investigational peptide drug conjugate linked to docetaxel, a well-established and well-characterized cytotoxic agent used in the. 4. com uses cookies on this site. (2022-02-24 | TSX:TH) Theratechnologies Reports Financial Results for Fiscal 2021 and Provides Business Update. We also use them to share usage. Microsoft to invest $500M in Quebec AI economy. (Translation of registrant’s name into English) 2310 Alfred-Nobel Boulevard . MONTREAL, Feb. We also use them to share usage. TH1902, a newly developed sortilin (SORT1)-targeted peptide-docetaxel conjugate is currently in phase-1 clinical trial. Northwest also announces an update on its. Cookies are used to offer you a better browsing experience and to analyze our traffic. . MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. stock price gained 6. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of a notification letter (the “Notification Letter. 46. (“Theratechnologies”, the “Company”, or “we”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that it has completed the previously announced consolidation of the issued. About Theratechnologies Theratechnologies (Nasdaq: THTX) (TSX: TH) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical. (2022-09-19 | TSX:TH) Theratechnologies to Present at the Cantor Oncology, Hematology & HemeOnc Conference. Track Theratechnologies Inc. FY2023 Revenue Guidance Range Confirmed Between $90 million and $95 million; Growth of the Commercial Portfolio in the Range of 13% and 19%. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. VANCOUVER, British Columbia, Nov. 29(+0. Apr 14, 2020, 8:30 a. com uses cookies on this site. licensed the product from TaiMed Biologics, Inc. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. TH | March 7, 2023. One reason for that is that this tier does not include penny stocks. A live webcast of Dr. Competitors: Unknown. The price has fallen in 7 of the last 10 days and is down by -30. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. It is the Company’s proprietary peptide linked to docetaxel – a commonly used cytotoxic agent used to treat many cancers. Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key Objectives. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F ¨ Form 40-F xToronto, Ontario-- (Newsfile Corp. F8 formulation intended to replace EGRIFTA SV® with simplified dosing for the treatment of excess abdominal fat in adults with HIV and lipodystrophy. S. (“Theratechnologies” or the “Company”) (TSX: TH) today announced that it has applied to list its common shares on NASDAQ. com uses cookies on this site. H4S 2B4 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨Theratechnologies has established its SORT1+ Technology™ platform as an engine for the development of proprietary peptide-drug conjugates (PDCs) that target the sortilin (SORT1) receptor, which is expressed in multiple tumor types. 28, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. com uses cookies on this site. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650WELCOME TO SEDAR+ File, disclose and search for issuer information in Canada’s capital markets Search SEDAR+ All public disclosure documents Reporting Issuers List Filing organizations from all jurisdictions Disciplined List People and companies under disciplinary action Cease Trade Orders People and companies restricted from trading securities Sign. With the company starting 2023 with 8,725 employees, that’s an 11. Visit the TSX ETF Investor Centre to access our screener and comparison tool. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or the Company (on a consolidated basis)) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on. Data presented at AMCP Nexus 2023. 2 million. , a biopharmaceutical company focused on the development and commercialization of innovative therapies, announced further changes to its operations that will see a tapering. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company will report financial results and provide a business update for its third. We also use them to share usage. Theratechnologies inc. It is the Company’s proprietary peptide linked to. Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. By continuing to use our service, you agree to our use of cookies. (2020-03-31 | tsx:th) theratechnologies provides business update related to current covid-19 situation Stockhouse. com uses cookies on this site. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that the Company will present data from tissue microarrays showing high. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. The Company currently commercializes two products in the field of HIV. 28 $1. Message Board Total Posts: 4. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. View real-time stock prices and stock quotes for a full financial overview. MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. GlobeNewswire. - Cash, bonds and money market funds of US$22. Who is Theratechnologies. Stockhouse. This news release constitutes a. FY2023 revenue guidance range set between $90 million and $95 million. Investor Relations. Trogarzo® and. Amount of cash a business has after it has met its financial obligations such as debt and outstanding payments. CA, an investment chat community for Canada's small cap marketsTheratechnologies is currently analyzing data and preparing responses to questions received from the FDA. is an employee of TaiMed Biologics USA, Inc. - Issued and outstanding common shares to be consolidated on the basis of 1 post-consolidation share for each 4 pre-consolidation shares issued and outstanding, to regain compliance with NASDAQ listing requirements. 40%) (As of 11/17/2023 ET) Compare Today's Range $1. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. Stock analysis for Theratechnologies Inc (TH:Toronto) including stock price, stock chart, company news, key statistics, fundamentals and company profile. T. Biopharma Theratechnologies (NASDAQ:THTX) Friday announced that a study evaluating an intramuscular (IM) method of administration for its therapy, Trogarzo, did not meet the primary endpoint. Thank you. Further. Stockhouse. MONTREAL, Feb. Montréal, Québec, Canada . Theratechnologies has generated ($1. Presented in part at the XVI International AIDS Conference; August 13–18, 2006; Toronto, Canada (abstracts TUP30058 AND THLB0218). By continuing to use our service, you agree to our use of cookies. Theratechnologies presented the pre-clinical and clinical data gathered thus far to the SAC, which made recommendations to modify the frequency of administration, selection of tumor types and. 1M. 04) earnings per share (EPS) for the quarter. Approximately US$2,000,000, or CA$2,600,000, was paid in cash at closing. lgibson. Montréal, Québec, Canada . About Theratechnologies Theratechnologies (TSX:TH) is a specialty pharmaceutical company addressing unmet medical needs to promote healthy ageing and an improved quality of life among HIV patients. This news release constitutes a “designated news release” for the purposes. 2. 67, which is an increase of 1,144. (2023-07-21 | TSX:TH) Theratechnologies Announces the Resignation of One of Its Directors, Mr. MONTREAL, April 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. MONTREAL, June 22, 2020 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 12, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. If you have HIV, it's important to know the difference. If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 9 million, adjusted EBITDA of $2. TH | February 28, 2023. Small cap stock market news and analysis, portfolio tracking, investor message boards and forums (bullboards), newsletter aggregation and detailed snapshots of stock quotes for. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. T. Theratechnologies Inc. (TH. This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021. Theratechnologies (TH) has announced preclinical findings for its peptide-drug conjugate TH1902 for the treatment of metastatic cancers. Stockhouse. Theratechnologies had a negative net margin of 36. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. TH | July 20, 2023. TO) stock quote, history, news and other vital information to help you with your stock trading and investing. MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. THERATECHNOLOGIES INC. com uses cookies on this site. Theratechnologies Announces Certain Preliminary Q3 2023 Financial Highlights. Focused on small-cap companies and sectors. TH | September 5, 2023. Theratechnologies Inc. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. TH1902 is a first-in-class PDC targeting SORT1, that consists of 2 molecules of docetaxel attached to the TH19P01 peptide via a cleavable succinyl linker. Stockhouse. Cookies are used to offer you a better browsing experience and to analyze our traffic. ("Theratechnologies" or the "Company"). Theratechnologies (TSX: TH) has posted net revenue estimates for fourth quarter and the full fiscal year ending Nov 30, 2020. . Last Reviewed: February 24, 2023. com uses cookies on this site. (2020-11-03 | TSX:TH) Theratechnologies Announces Departure of Chief Commercial Officer. Theratechnologies to Announce Financial Results for Its First Quarter 2022. com uses cookies on this site. Stockhouse. Our research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the. CALGARY, AB, May 12, 2022 /PRNewswire/ - Exro Technologies Inc. Theratechnologies (THTX) Stock Price, News & Analysis $1. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. By Nick Paul Taylor Jul 12, 2023 8:57am. - Cash, bonds and money market funds of US$22. Get the latest Theratechnologies Inc (THTX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Cookies are used to offer you a better browsing experience and to analyze our traffic. In collaboration with the University of Manitoba (UM), the company demonstrated that its photodynamic compound. Theratechnologies was founded in 1993 and currently employs more than 150 people in Canada, the United States and Europe. Cookies are used to offer you a better browsing experience and to analyze our. 33. TORONTO, May 19, 2023. The webinar will also address system-level barriers and present real-world. 617-356-1009. THERATECHNOLOGIES INC. 00 in the next twelve months. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced receipt of the 2023 Industrial Research Sectoral Group (RSRI) Innovation Award from the CQDM (for. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the Company’s participation in three poster presentations at the 2022 Annual Meeting. By continuing to use our service, you agree to our use of cookies. was a. MONTREAL, April 12, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. is a speaker and consultant of Theratechnologies. com uses cookies on this site. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. (2022-09-12 | TSX:TH) Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Fri, 17 Apr 2015 15:08:33 GMT ~ Supreme Court of Canada rules in favour of Theratechnologies. 04, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (NASDAQ:THTX) Q3 2021 Earnings Call October 13, 2021 8:30 A. Heures de négociation. 26, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Stockhouse. Theratechnologies Inc. MONTREAL, Sept. 4%. 60%. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today reported business highlights and financial results for the third quarter of fiscal year 2022, ended August. Cookies are used to offer you a better browsing experience and to analyze our traffic. It is highly expressed in cancer cells compared to healthy tissue, which makes SORT1 an. The company’s previously announced offering was conducted by a syndicate of underwriters, including companies such as Canaccord Genuity. See the latest Theratechnologies Inc stock price (THTX:XNAS), related news, valuation, dividends and more to help you make your investing decisions. 72%. 33 +0. Theratechnologies Europe Limited 1st Floor, 12 Duke Lane Upper Royal Hibernian Way DUBLIN Dublin 2 Ireland D02 DX07 Phone: +353 1 215 0650For the three- and six-month periods ended May 31, 2023, consolidated revenue was $17,549,000 and $37,457,000, compared to $19,268,000 and $37,825,000 for the same periods ended May 31, 2022. (THTX) stock. Theratechnologies (TSX: TH) (NASDAQ: THTX) is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a. ET. MONTREAL, Oct. MONTREAL, Sept. Stockhouse. Find the latest Theratechnologies Inc. THTX | Complete Theratechnologies Inc. (2022-02-10 | TSX:TH) Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021. The financial results presented in this press release are taken from the. Unveiling Silvercorp's golden potential at the Ying Mining District. ir@theratech. 71. TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (Sort1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth Sep 13. THERATECHNOLOGIES INC. m. This news release constitutes a “designated news release” for the purposes of the. – Form 40-F for Fiscal Year Ended November 30, 2011 – Your File No. Further information about Theratechnologies is available on the Company's website at on SEDAR at and on EDGAR at MONTREAL, April 03, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. Phone Number 15143319691. 01, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. 30, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. TORONTO, Sept. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a.